TD Cowen lowered the firm’s price target on PacBio (PACB) to $3.50 from $4 and keeps a Buy rating on the shares. The firm said its sales guidance was below consensus bt long-term, they see an attractive opportunity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Pacific Biosciences: Strategic Growth Amidst Funding Challenges Supports Buy Rating
- PacBio Navigates Financial Challenges with Strategic Advances
- Pacific Biosciences: Buy Rating Amidst Conservative Guidance and Strategic Growth Initiatives
- PacBio reports Q4 EPS (20c), consensus (17c)
- Pac Bio options imply 11.8% move in share price post-earnings